Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JAB-30355 |
Synonyms | |
Therapy Description |
JAB-30355 is a selective TP53 Y220C reactivator, which increases expression of TP53 target genes and potentially decreases tumor cell viability and inhibits growth of tumors harboring TP53 Y220C (Cancer Res (2024) 84 (6_Supplement): 5940). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JAB-30355 | JAB 30355|JAB30355 | JAB-30355 is a selective TP53 Y220C reactivator, which increases expression of TP53 target genes and potentially decreases tumor cell viability and inhibits growth of tumors harboring TP53 Y220C (Cancer Res (2024) 84 (6_Supplement): 5940). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06386146 | Phase Ib/II | JAB-30355 | JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation | Recruiting | USA | 1 |